Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Shares Down 9 Percent After Warning of Slowdown in 500K Array Market

NEW YORK, Feb. 28 (GenomeWeb News) - Affymetrix shares were down 9.1 percent,or $3.58, at $35.77 in afternoon trade amid general weakness in drug stocks and following an SEC filing in which the company said that "the market for whole genome mapping products has temporarily slowed."

 

In the filing, Affymetrix announced the opening of a new probe array manufacturing facility in Singapore. It also reported that recent production yields on its Mapping 500K array set "consistently exceed 75 percent" in its Sacramento,Calif., facility and that it expected to meet customer demand for the product in 2006.

 

However, the company noted that "since many customers complete projects before reordering, this may affect the timing of the 500K product reorders" and that these "factors ... may increase the risk around our expected revenue targets for the Mapping 500K Array Set."

 

Affymetrix did not announce a revenue target for the 500K, and has not in the past.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.